| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 08/02/2001 | WO2001055112A1 Method for preparing alpha-sulfonyl hydroxamic acid derivatives |
| 08/02/2001 | WO2001055106A2 Novel melanocortin receptor agonists and antagonists |
| 08/02/2001 | WO2001055105A1 N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv |
| 08/02/2001 | WO2001055101A2 A new process for the preparation of latanoprost |
| 08/02/2001 | WO2001055094A1 Monohydrate of cis-lithium-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexanecarboxylate |
| 08/02/2001 | WO2001055086A1 Alkynylsubstituted propionic acid derivatives and their use against diabetes and obesity |
| 08/02/2001 | WO2001054771A2 Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor |
| 08/02/2001 | WO2001054731A2 Ligand conjugates and methods for preparing same |
| 08/02/2001 | WO2001054730A1 METHOD FOR PRODUCING A COENZYME Q10 / η-CYCLODEXTRIN COMPLEX |
| 08/02/2001 | WO2001054728A1 NOVEL REMEDIES WITH THE USE OF β3 AGONIST |
| 08/02/2001 | WO2001054724A1 Anticancer compositions |
| 08/02/2001 | WO2001054723A1 Therapeutic method for reducing angiogenesis |
| 08/02/2001 | WO2001054711A2 Use of neurotoxins for treating diabetes |
| 08/02/2001 | WO2001054702A1 Novel compounds |
| 08/02/2001 | WO2001054699A1 Selective estrogen receptor modulators in combination with estrogens |
| 08/02/2001 | WO2001054694A1 Tetrahydropyrimidone inhibitors of fatty acid binding protein and method |
| 08/02/2001 | WO2001054685A1 Mucin synthesis inhibitors |
| 08/02/2001 | WO2001054683A1 Ibuprofen containing active agent preparation |
| 08/02/2001 | WO2001054682A1 Remedies |
| 08/02/2001 | WO2001054681A2 Composition for treatment of stress |
| 08/02/2001 | WO2001054680A2 Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor |
| 08/02/2001 | WO2001054677A2 Ace inhibitor-vasopressin antagonist combinations |
| 08/02/2001 | WO2001054669A1 Pharmaceutical compositions comprising a hmg coa reductase inhibitor |
| 08/02/2001 | WO2001054668A1 Pharmaceutical compositions comprising a hmg reductase inhibitor |
| 08/02/2001 | WO2001054667A1 Electrospun pharmaceutical compositions |
| 08/02/2001 | WO2001016114A3 Heterocyclic compounds and methods for modulating cxcr3 function |
| 08/02/2001 | WO2001014584A3 Methods of identifying anti-viral agents |
| 08/02/2001 | WO2001012189A8 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents |
| 08/02/2001 | WO2001007065A3 PRODUCTION OF rhPBGD AND NEW THERAPEUTIC METHODS FOR TREATING PATIENTS WITH ACUTE INTERMITTENT PORPHYRIA (AIP) AND OTHER PORPHYRIC DISEASES |
| 08/02/2001 | WO2001005826A3 Chimeric polypeptides of serum albumin and uses related thereto |
| 08/02/2001 | WO2001004305A3 Human proteins involved in detoxification |
| 08/02/2001 | WO2001004146A3 Ecarin polypeptides, polynucleotides encoding ecarin, and methods for use thereof |
| 08/02/2001 | WO2000076971A3 Serine protease inhibitors |
| 08/02/2001 | WO2000069898A3 Molecular interactions in allergy cells |
| 08/02/2001 | WO2000066564A8 Benzimidazolones and analogues and their use as progesterone receptor ligands |
| 08/02/2001 | WO2000066175A3 Conjugates as therapies for cancer and prostate diseases |
| 08/02/2001 | WO2000046391A9 Genes displaying enhanced expression during cellular senescence and terminal cell differentiation and uses thereof |
| 08/02/2001 | WO1999066918A8 Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor |
| 08/02/2001 | US20010011146 Pevention cell degradation |
| 08/02/2001 | US20010011136 Anticancer agents |
| 08/02/2001 | US20010011135 Anticancer agents |
| 08/02/2001 | US20010011134 Cyclic and heterocyclic N-substituted alpha-iminohydroxamic and -carboxylic acids |
| 08/02/2001 | US20010011127 Modulating activity of endogenous protein |
| 08/02/2001 | US20010011124 Genetic engineering |
| 08/02/2001 | US20010011097 Methods and compositions for treating and preventing mucositis |
| 08/02/2001 | US20010011093 Arylgycinamide derivatives, methods of producing these substances and pharmaceutical compositions containing such compounds |
| 08/02/2001 | US20010011092 High affinity ligands for nociceptin receptor ORL-1 |
| 08/02/2001 | US20010011091 Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists |
| 08/02/2001 | US20010011085 4-substituted cephem derivatives as elastase inhibitors |
| 08/02/2001 | US20010011084 Use of estrogen to modify the amount of serotonin transporter or its mrna |
| 08/02/2001 | US20010011077 Secreted cysteine rich protein-6 (SCRP-6); polynucleotides and processes for producing polypeptides |
| 08/02/2001 | US20010011072 Skin disorders; kidney and liver disorders |
| 08/02/2001 | US20010010935 Useful in treating stem cells in a patient undergoing chemotherapy |
| 08/02/2001 | US20010010934 Polypeptides that regulate epithelial specific gene expression; hypoproliferative disorders; medical diagnosis |
| 08/02/2001 | US20010010924 Inflammation, arthritis, septicemia, brain injury, autoimmune (inflammatory bowel, psoriasis)/bone/acute respiratory diseases, restenosis, AIDS, cancer (lympho-proliferative disorders, atheroscleosis, and Alzheimer's |
| 08/02/2001 | US20010010913 Isolated polypeptide |
| 08/02/2001 | DE10038108A1 Pharmazeutische Zusammensetzungen Pharmaceutical compositions |
| 08/02/2001 | DE10011926A1 Genetisch veränderte Fibroblastenzellen Genetically modified fibroblast cells |
| 08/02/2001 | DE10004157A1 New pyridyl- or pyrimidinyl-substituted bicyclic pyrrole derivatives, are cyclokine release inhibitors useful for treating immune system-related disorders, e.g. cancer, multiple sclerosis or arthritis |
| 08/02/2001 | DE10003757A1 Ibuprofen-Wirkstoffzubereitung Ibuprofen drug preparation |
| 08/02/2001 | CA2398821A1 Composition for treatment of stress |
| 08/02/2001 | CA2398728A1 Novel melanocortin receptor agonists and antagonists |
| 08/02/2001 | CA2398660A1 Human cyr61 |
| 08/02/2001 | CA2398643A1 Novel compounds |
| 08/02/2001 | CA2398642A1 Mucin synthesis inhibitors |
| 08/02/2001 | CA2398615A1 Benzoxathiepino[3,4-b]pyridine derivatives, process for their preparation and their use as medicaments |
| 08/02/2001 | CA2398561A1 Method for preparing alpha-sulfonyl hydroxamic acid derivatives |
| 08/02/2001 | CA2398546A1 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 08/02/2001 | CA2398503A1 Therapeutic method for reducing angiogenesis |
| 08/02/2001 | CA2398435A1 Novel ligands and methods for preparing same |
| 08/02/2001 | CA2398430A1 Human protein kinases and protein kinase-like enzymes |
| 08/02/2001 | CA2398358A1 The neurosteroid dhea as a marker for neuropathologies |
| 08/02/2001 | CA2398304A1 A new process for the preparation of latanoprost |
| 08/02/2001 | CA2398288A1 Ibuprofen containing active agent preparation |
| 08/02/2001 | CA2398227A1 17 human secreted proteins |
| 08/02/2001 | CA2398199A1 Novel therapeutic agents that use a .beta.3 agonist |
| 08/02/2001 | CA2398173A1 Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases |
| 08/02/2001 | CA2398104A1 Polymorphisms in the human cyp2d6 gene promoter region and their use in diagnostic and therapeutic applications |
| 08/02/2001 | CA2397991A1 Diagnosis of tauopathies determining tau/phospho-tau ratio |
| 08/02/2001 | CA2397758A1 Monohydrate of cis-lithium-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexanecarboxylate |
| 08/02/2001 | CA2397493A1 Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 08/02/2001 | CA2397267A1 Peptide fragments and uses thereof as type-1 interferon antagonist |
| 08/02/2001 | CA2396640A1 Electrospun pharmaceutical compositions |
| 08/02/2001 | CA2396596A1 Tetrahydropyrimidone inhibitors of fatty acid binding protein and method |
| 08/02/2001 | CA2396372A1 Alkynylsubstituted propionic acid derivatives and their use against diabetes and obesity |
| 08/02/2001 | CA2395730A1 Selective estrogen receptor modulators in combination with estrogens |
| 08/02/2001 | CA2394525A1 Pyridopyrimidinone derivatives for treatment of neurodegenerative disease |
| 08/01/2001 | EP1120410A1 Nicotinic acid esters useful as CNS agents and having affinity for 5-HT receptors |
| 08/01/2001 | EP1120409A1 2,3-disubstituted pyridine derivatives, process for the preparation thereof, drug compositions containing the same and intermediates for the preparation |
| 08/01/2001 | EP1120114A2 Compositions and methods for treating conditions responsive to estrogen |
| 08/01/2001 | EP1120113A2 Use of selective ligands for treatment of disease states responsive to steroid or steroid-like hormone |
| 08/01/2001 | EP1119629A2 Oxidoreductase molecules |
| 08/01/2001 | EP1119622A2 Bax-mediated apoptosis modulating reagents and methods |
| 08/01/2001 | EP1119619A2 Nlk1 -interacting proteins |
| 08/01/2001 | EP1119614A2 Protein tyrosine phosphatase-1b (ptp-1b) deficient mice and uses thereof |
| 08/01/2001 | EP1119581A1 METHODS OF INHIBITING SMOOTH MUSCLE CELL PROLIFERATION AND PREVENTING RESTENOSIS WITH A VECTOR EXPRESSING RB2/p130 |
| 08/01/2001 | EP1119579A1 Antisense modulation of bcl-x expression |
| 08/01/2001 | EP1119571A2 Tricyclic delta3-piperidines as alpha2-antagonists |
| 08/01/2001 | EP1119570A1 Tricyclic delta3-piperidines as pharmaceuticals |
| 08/01/2001 | EP1119564A1 Aryl- 4-fluoro-4- (2-pyridin-2-yl-ethylamino)-methyl]-piperidin-1-yl -methanone derivatives as 5-ht1 receptor antagonists |